Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $16.00 Consensus Target Price from Brokerages

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $16.00.

Several analysts have recently weighed in on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a report on Wednesday, February 18th. BTIG Research raised their price objective on shares of Coya Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen raised Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, February 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st.

Coya Therapeutics Price Performance

NASDAQ:COYA opened at $4.96 on Friday. The firm has a market cap of $103.76 million, a price-to-earnings ratio of -4.47 and a beta of 0.23. The firm’s fifty day moving average price is $4.92 and its 200 day moving average price is $5.70. Coya Therapeutics has a 1-year low of $3.94 and a 1-year high of $8.29.

Institutional Investors Weigh In On Coya Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new stake in shares of Coya Therapeutics in the fourth quarter valued at about $196,000. State Street Corp grew its position in Coya Therapeutics by 44.5% during the fourth quarter. State Street Corp now owns 69,510 shares of the company’s stock worth $403,000 after buying an additional 21,410 shares during the period. Alyeska Investment Group L.P. purchased a new position in Coya Therapeutics in the fourth quarter valued at about $4,640,000. AWM Investment Company Inc. purchased a new position in Coya Therapeutics in the fourth quarter valued at about $4,205,000. Finally, Walleye Capital LLC acquired a new stake in shares of Coya Therapeutics during the 4th quarter valued at approximately $215,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.